OOIR: Observatory of International Research

Papers

(The H4-Index of npj Vaccines is 41. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine	227
Vaccination against Onchocerca volvulus induces IgG-mediated protective immunity dependent on neutrophils and complement	155
Impact of genotypic variability of measles virus T-cell epitopes on vaccine-induced T-cell immunity	127
Reverse development of vaccines against antimicrobial-resistant pathogens	120
Microneedle patch as a new platform to effectively deliver inactivated polio vaccine and inactivated rotavirus vaccine	119
Zika purified inactivated virus (ZPIV) vaccine reduced vertical transmission in pregnant immunocompetent mice	94
Analyzing atomic force microscopy images of virus-like particles by expectation-maximization	91
Intranasal vaccine for Lyme disease provides protection against tick transmitted Borrelia burgdorferi beyond one year	83
A viral codon usage strategy enhances antigen production and protection in SFTSV mRNA vaccination	80
Tetravalent microprojection-based dengue chimeric virus vaccine raises potent neutralising antibodies in mice	80
Immunogenic arenavirus vector SIV vaccine reduces setpoint viral load in SIV-challenged rhesus monkeys	74
Safety and immunogenicity of the Sm-p80 GLA-SE schistosomiasis vaccine	70
Mapping global public perspectives on mRNA vaccines and therapeutics	70
Risk assessment of retinal vascular occlusion after COVID-19 vaccination	69
Assessing immunogenicity barriers of the HIV-1 envelope trimer	67
Functionality and translation fidelity characterization of mRNA vaccines using platform based mass spectrometry detection	65
A potent and durable malaria transmission-blocking vaccine designed from a single-component 60-copy Pfs230D1 nanoparticle	64
Immunogenicity and safety of a rabies-based highly pathogenic influenza A virus H5 vaccine in cattle	64
The dengue-specific immune response and antibody identification with machine learning	62
Baseline mapping of Oropouche virology, epidemiology, therapeutics, and vaccine research and development	60
Influenza A virus in dairy cattle: infection biology and potential mammary gland-targeted vaccines	57
Effective vaccination strategy using SARS-CoV-2 spike cocktail against Omicron and other variants of concern	57
Rational development of a combined mRNA vaccine against COVID-19 and influenza	55
Immunogenicity and protective efficacy of a rhesus adenoviral vaccine targeting conserved COVID-19 replication transcription complex	54
Diversity of immunization strongly impacts SARS-CoV-2 antibody function surrogates	54

Immune response induced by standard and fractional doses of 17DD yellow fever vaccine	52
GP38 as a vaccine target for Crimean-Congo hemorrhagic fever virus	51
Antibody responses against influenza A decline with successive years of annual influenza vaccination	51
Author Correction: A Pvs25 mRNA vaccine induces complete and durable transmission-blocking immunity to Plasmodium vivax	49
Human in vitro modeling of adjuvant formulations demonstrates enhancement of immune responses to SARS-CoV-2 antigen	49
A rationally designed antigen elicits protective antibodies against multiple nosocomial Gram-positive pathogens	49
Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants	48
Single-dose intranasal adenovirus-based RSV vaccines targeting G and M2	47
Genome-wide association study of myocarditis and pericarditis following COVID-19 vaccination	46
IL-12 mRNA-LNP promotes dermal resident memory CD4+ T cell development	46
Next-gen novel nanocage-based multivalent vaccine candidate to tackle the rising menace of Mpox	46
Tick-borne encephalitis vaccine breakthrough infections induce aberrant T cell and antibody responses to non-structural proteins	45
Restricted valency (NPNA)n repeats and junctional epitope-based circumsporozoite protein vaccines against Plasmodium falciparum	44
Leishmania tarentolae as a platform for the production of vaccines against viral pathogens	43
Immunogenicity and efficacy of homologous and heterologous NDV and MVA SARS-CoV-2 vaccines in mice and hamsters	41
A register and questionnaire study of long-term general health symptoms following SARS-CoV-2 vaccination in Denmark	41